Back to Search Start Over

Rapidly absorbed orodispersible tablet containing molecularly dispersed felodipine for management of hypertensive crisis: development, optimization and in vitro/in vivo studies.

Authors :
Basalious EB
El-Sebaie W
El-Gazayerly O
Source :
Pharmaceutical development and technology [Pharm Dev Technol] 2013 Mar-Apr; Vol. 18 (2), pp. 407-16. Date of Electronic Publication: 2012 Feb 18.
Publication Year :
2013

Abstract

A liquisolid orodispersible tablet of felodipine, a BCS Class II drug, was developed to improve drug dissolution and absorption through the buccal mucosa for management of hypertensive crisis. A 24 full-factorial design was applied to optimize felodipine liquisolid systems (FLSs) having acceptable flow properties and possessing enhanced drug dissolution rates. Four formulation variables; The liquid type, X1 (PG or PEG), drug concentration, X2 (10% and 20%), type of coat, X3 (Aerosil® and Aeroperl®) and excipients ratio, X4 (10 and 20) were included in the design. The systems were assessed for dissolution and flow properties. Following optimization, the formulation components (X1, X2, X3 and X4) were PEG, 10%, Aerosil® and 20, respectively. The optimized FLS was compressed into felodipine liquisolid orodispersible tablet using Prosolv® as carrier material (FLODT-2). The in vitro and in vivo disintegration times of FLODT-2 were 9 and 7 s, respectively. The in vivo pharmacokinetic study using human volunteers showed a significant increase in dissolution and absorption rates of the formulation of FLODT-2 compared to soft gelatin capsules filled with felodipine solution in PEG under the same conditions. Our results proposed that the optimized FLODT formulation could be promising to manage hypertensive crisis.

Details

Language :
English
ISSN :
1097-9867
Volume :
18
Issue :
2
Database :
MEDLINE
Journal :
Pharmaceutical development and technology
Publication Type :
Academic Journal
Accession number :
22339303
Full Text :
https://doi.org/10.3109/10837450.2012.659258